Skip to main content
40°
Clear
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by BeiGene
< Previous
1
2
3
Next >
BeiGene to Demonstrate Strength of Hematology Portfolio and Pipeline at European Hematology Association 2022 Congress
May 12, 2022
From
BeiGene
Via
Business Wire
Tickers
BGNE
BeiGene Announces the Approval in China of BLINCYTO® (Blinatumomab) for Injection for Pediatric Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)
May 04, 2022
From
BeiGene
Via
Business Wire
Tickers
BGNE
BeiGene Breaks Ground on New Manufacturing and Clinical R&D Center at the Princeton West Innovation Campus in New Jersey
April 29, 2022
From
BeiGene
Via
Business Wire
Tickers
BGNE
BeiGene Announces BRUKINSA (zanubrutinib) Approval in Uruguay in Mantle Cell Lymphoma, Marginal Zone Lymphoma, and Waldenström’s Macroglobulinemia
April 28, 2022
From
BeiGene
Via
Business Wire
Tickers
BGNE
BeiGene to Present Clinical Data from Innovative Oncology Portfolio at 2022 ASCO Annual Meeting
April 27, 2022
From
BeiGene
Via
Business Wire
Tickers
BGNE
Global Phase 3 Trial of BeiGene’s PD-1 Inhibitor, Tislelizumab, in Combination with Chemotherapy Meets Primary Endpoint in First-Line Advanced Esophageal Squamous Cell Carcinoma
April 27, 2022
From
BeiGene
Via
Business Wire
Tickers
BGNE
BeiGene Provides Grant to Crossroads4Hope to Fund Psychosocial Support Programs for Cancer Patients and Communities in New Jersey
April 21, 2022
From
BeiGene
Via
Business Wire
Tickers
BGNE
BeiGene Presents Updated Results from Phase 3 RATIONALE-309 Trial of PD-1 Inhibitor Tislelizumab in First-Line RM-NPC in Virtual ASCO Plenary Series
April 19, 2022
From
BeiGene
Via
Business Wire
Tickers
BGNE
China NMPA Approves Tislelizumab for Patients with Second-Line Esophageal Squamous Cell Carcinoma
April 15, 2022
From
BeiGene
Via
Business Wire
Tickers
BGNE
BeiGene to Present Clinical Results and Biomarker Data on Tislelizumab in Solid Tumors at the AACR Annual Meeting 2022
April 08, 2022
From
BeiGene
Via
Business Wire
Tickers
BGNE
BeiGene Announces European Medicines Agency Acceptance of Marketing Authorization Applications for Tislelizumab for the Treatment of Patients with ESCC and NSCLC
April 06, 2022
From
BeiGene
Via
Business Wire
Tickers
BGNE
BeiGene and Medison Announce Approval and National Reimbursement in Israel for BRUKINSA® (zanubrutinib) for the Treatment of Waldenström's Macroglobulinemia
March 15, 2022
From
BeiGene
Via
Business Wire
Tickers
BGNE
BeiGene Announces European Medicines Agency Acceptance of Applications for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia and Marginal Zone Lymphoma
February 22, 2022
From
BeiGene
Via
Business Wire
Tickers
BGNE
BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia
February 22, 2022
From
BeiGene
Via
Business Wire
Tickers
BGNE
BeiGene Announces Approval for BRUKINSA (zanubrutinib) by Swissmedic for Treatment of Adult Patients with Waldenström’s Macroglobulinemia
February 17, 2022
From
BeiGene
Via
Business Wire
Tickers
BGNE
Drs. Margaret Dugan and Alessandro Riva Appointed to BeiGene Board of Directors
February 01, 2022
From
BeiGene
Via
Business Wire
Tickers
BGNE
BeiGene Announces Acceptance of Supplemental New Drug Application in China for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia with Breakthrough Therapy Designation
January 28, 2022
From
BeiGene
Via
Business Wire
Tickers
BGNE
BeiGene Announces Positive Findings from Phase 3 Trial of Tislelizumab in Combination with Chemotherapy in First-Line Gastric or Gastroesophageal Junction Cancer
January 24, 2022
From
BeiGene
Via
Business Wire
Tickers
BGNE
BeiGene Announces Acceptance of a Supplemental New Drug Application in China for BRUKINSA (zanubrutinib) in Waldenström’s Macroglobulinemia
January 20, 2022
From
BeiGene
Via
Business Wire
Tickers
BGNE
China NMPA Approves Tislelizumab as Second- or Third-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer
January 06, 2022
From
BeiGene
Via
Business Wire
Tickers
BGNE
Nanjing Leads Biolabs and BeiGene Announce Worldwide License and Collaboration Agreement for LBL-007 Anti-LAG-3 Antibody; BeiGene Granted Exclusive Commercialization Rights Outside of China
December 13, 2021
From
BeiGene
Via
Business Wire
Tickers
BGNE
BeiGene Presents Results from SEQUOIA Trial of BRUKINSA (zanubrutinib) in First-Line Chronic Lymphocytic Leukemia at the 63rd ASH Annual Meeting
December 12, 2021
From
BeiGene
Via
Business Wire
Tickers
BGNE
BeiGene Presents Updated Safety and Efficacy Findings on BRUKINSA (zanubrutinib) in BTK Inhibitor-Intolerant Patients with Relapsed or Refractory B-Cell Malignancies
December 11, 2021
From
BeiGene
Via
Business Wire
Tickers
BGNE
BeiGene Presents Results from Phase 3 Trial of Tislelizumab in Nasopharyngeal Cancer at ESMO Immuno-Oncology Congress 2021
December 10, 2021
From
BeiGene
Via
Business Wire
Tickers
BGNE
BeiGene Announces Inclusion in the China National Reimbursement Drug List (NRDL) of Tislelizumab in Three New Indications, BRUKINSA® (Zanubrutinib) in One New Indication, and the First Listing for Pamiparib
December 02, 2021
From
BeiGene
Via
Business Wire
Tickers
BGNE
BeiGene to Present New Clinical Data on Tislelizumab at ESMO IO Congress 2021
December 02, 2021
From
BeiGene
Via
Business Wire
Tickers
BGNE
BeiGene Announces Approval of BRUKINSA (zanubrutinib) in the European Union for Treatment of Adults with Waldenström’s Macroglobulinemia
November 23, 2021
From
BeiGene
Via
Business Wire
Tickers
BGNE
BeiGene Initiates First-in-Human Phase 1 Clinical Trial of Investigational TYK2 Inhibitor BGB-23339
November 22, 2021
From
BeiGene
Via
Business Wire
Tickers
BGNE
BeiGene and NewBridge Pharmaceuticals Announce Approval in Saudi Arabia of BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma
November 14, 2021
From
BeiGene
Via
Business Wire
Tickers
BGNE
BeiGene to Present Clinical Data on BRUKINSA in Chronic Lymphocytic Leukemia at the 63rd ASH Annual Meeting
November 04, 2021
From
BeiGene
Via
Business Wire
Tickers
BGNE
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.